UFP Technologies (UFPT) is back on investors’ radar after recent share price moves, prompting a closer look at how its medical and engineered packaging business lines up with current expectations and recent return trends.

At a share price of $237.20, UFP Technologies has seen short term share price softness, with a 1 month share price return of 2.37% and a 7 day share price return of 2%. However, the 90 day share price return of 18.56% and 5 year total shareholder return of 296.79% point to longer term momentum that contrasts with the 1 year total shareholder return, which is down 1.95%.

If recent moves in UFP Technologies have you reassessing your watchlist, this can be a useful moment to broaden the search and tap into 18 top founder-led companies

UFP Technologies is trading at a clear gap to both analyst targets and intrinsic value estimates, raising a simple issue for investors looking at the recent pullback: where does fair value actually sit within that spread?

Price to earnings for UFP Technologies, is the premium worth it?

Right now UFP Technologies carries a P/E of 26.7x, and when that is set against both fair value estimates and peers, it paints a mixed picture for investors watching the recent pullback.

The P/E ratio compares the company’s share price to its earnings per share, so a higher figure usually signals that the market is paying more for each dollar of current earnings. For a medical equipment and packaging business like UFP Technologies, this often reflects expectations around future growth, earnings quality and the resilience of its end markets rather than just the latest quarter.

On one hand, UFP Technologies screens as expensive against an estimated fair P/E of 23x. This implies the current 26.7x leaves a premium over what the SWS fair ratio suggests the market could move toward. On the other hand, that same 26.7x is described as good value relative to a peer average of 45.4x, even though it sits slightly above the wider US Medical Equipment industry average of 26.4x. This reinforces that investors are paying up, but not at the top end of sector valuations.

Result: Price-to-earnings of 26.7x (OVERVALUED)

However, UFP Technologies still faces risks if medical device demand softens or defense and industrial customers trim orders. This could pressure revenue and challenge the current valuation premium.

Another view on UFP Technologies’ valuation

While the P/E of 26.7x makes UFP Technologies look a little rich versus its 23x fair ratio, the SWS DCF model points the other way, with an estimated future cash flow value of $290.19 against a share price of $237.20. This suggests the stock trades below that fair value line. Which signal should carry more weight for you?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out UFP Technologies for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals around UFP Technologies leave you unsure, treat that as a prompt to review the data now and decide where you stand by weighing the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond UFP Technologies?

If UFP Technologies has sharpened your focus on quality, do not stop here. Use this momentum to scan the market for other stocks that fit your criteria.

• Target resilient businesses by running your filters through the 81 resilient stocks with low risk scores and see which companies line up with a more measured risk profile.
• Hunt for attractively priced opportunities by checking the 49 high quality undervalued stocks that match your view on quality and valuation discipline.
• Spot future standouts early by scanning the screener containing 20 high quality undiscovered gems before they move onto everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.